CN1016785B - 9-去氧-9a-氮杂-9a-甲基-高红霉素A二水合物的制备方法 - Google Patents
9-去氧-9a-氮杂-9a-甲基-高红霉素A二水合物的制备方法Info
- Publication number
- CN1016785B CN1016785B CN88104331A CN88104331A CN1016785B CN 1016785 B CN1016785 B CN 1016785B CN 88104331 A CN88104331 A CN 88104331A CN 88104331 A CN88104331 A CN 88104331A CN 1016785 B CN1016785 B CN 1016785B
- Authority
- CN
- China
- Prior art keywords
- dihydrate
- azithromycin
- water content
- water
- monohydrate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/52—Two oxygen atoms
- C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
- C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
- C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
- C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cardiology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Heart & Thoracic Surgery (AREA)
- Biotechnology (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Saccharide Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明公开了不吸湿的azithromycin(9-去氧-9a-氮杂-9a-甲基-9a-高红霉素A)二水合物及其制备方法。
Description
本发明涉及一种有效的新颖形式的azithromycin(9-去氧-9a-氮杂-9a-甲基-9a-高红霉素A),即:它的不吸湿的二水合物形式。
Azithromycin(9-去氧-9a-氮杂-9a-甲基-9a-高红霉素A)的属名是U.S.A.N.,一种由红霉素A衍生的广谱抗菌素化合物。Azithromycin分别是由Bright在美国专利4,474,768号和Kobrehel等人在美国专利4,517,359号中披露的。在这些专利中,发明者用了“N-甲基-11-氮杂-10-去氧-10-二氢红霉素A”这一命名。本发明的更***的命名基于“IUPAC Nomenclature of Organic Chemistry,1979 Edition”,Perg-amon Press,1979,PP.68-70,459,500-503上的开环和置换命名原则。
如先有技术所述,azithromycin是由乙醇和水结晶得到的(例如见美国专利4,474,768号中的实施例3),是吸湿的一水合物(详见下面制备例1)。由于其吸湿性,极难制备和维持具有恒定的、可再现的含水型的所述一水合物。在配制过程中尤难处理,因为在较高的相对湿度时,一般需要避免静电之麻烦(如:流速,带电位的起尘引起的***);一水合物易吸收不定量的水份,其吸湿量取决于曝光时间和相对湿度的精确值(见下面制备例1)。本发明的稳定的二水合物解决了上述难点。在有益于配制azithromycin的相对湿度状态下,该二水合物基本上是不吸湿的。
本发明涉及一种有效的新颖形式的azithromycin,即:在至少为两摩尔当量的水的存在下,由四氢呋喃和脂族(C-C)烃结晶制得的结晶
的不吸湿二水合物。
Azithromycin的结构式如下:
该化合物衍生于不含有不对称中心的红霉素A,因此在其每个如同红霉素A一样的这类中心(*),都存在立体化学结构。根据红霉素A衍生物的***命名,该化合物称为9-去氧-9a-氮杂-9a-甲基-9a-高红霉素A。包含本发明的二水合物的Azithromycin具有广谱抗菌素活性,用于治疗易受细菌感染的哺乳动物(包括人)。
“脂族(C5-C7)烃”是指沸点较低的烃溶剂,通常为有特定的沸点范围如通常所指的“戊烷”、“己烷”、“己烷类”等一类的混合物,但也可以是基本上纯的正己烷、环己烷或甲基环己烷。优选的烃溶剂是所谓的“己烷”,其沸点接近于纯的正己烷的沸点。
本发明易于实施。把呈无定形态的Azithromycin(按上述Bright或Kobrehel等的方法制得)或呈一水合物(由于吸水性,可能含一摩尔当量以上的水份)的Azithromycin溶于四氢呋喃。因为本方法初速阶段所需的温度并不关键,所以通常采用室温,从而省掉了加热和冷却的费用。此外,为获得最高的收率,并使溶剂用量、劳动力和设备成本最低,将四氢呋喃的体积保持在接近于最低的水平上,例如每公斤基质使用2升溶剂。采用惯用的过滤法,可方便地除去此阶段中存在的任何不溶性杂质。必要时,可用活性炭将混合物脱色。为了便于处理,在需要时,先用一部分(C5-C7)烃将高度浓缩的混合物稀释,然后过滤。若进入主体的水份大大超过一摩尔当量,例如接近2摩尔当量,则最好用硫酸镁一类的干燥剂将混合物干燥一段时间,特别是烃溶剂是在过滤前加入的情况下。为获得结晶的二水合物,将一定量的水加到所形成的纯净溶液中,以便足以使总的含水量达到相当于至少为2摩尔当量的水平,一般不超过3-4摩尔当量。用标准的费歇尔(Kare Fischer)滴定法,可方便地监测***中的含水量。先加水,继之以加烃溶剂(若过滤前混合物已经过稀释,则加入较多的烃溶剂),促使生成所期望的二水合物的结晶。这一步骤可在室温(如17-30℃)下实施,但为便于最初的结晶,最好于稍高温(如30-40℃)下进行。所采用的烃溶剂的总体积一般至少四倍于四氢呋喃。烃的体积较大,效果就理想,但为使成本最低,一般不这样做。一旦结晶完毕,通常于室温下粒化一段时间(如3-24小时),然后过滤收集产物。一般,将有机溶剂真空干燥(于20-40℃,一般于室温下进行较方便)后,得到产物。为避免水合过程中水份的损失,在干燥期间,一般要监测挥发组分和含水量,以便使四氢呋喃和烃的含量落在0.25%以下,含水量在理论值(4.6%)的0.3%偏差内。
按Bright在美国专利4,474,768号(这里用作对比文献)中详述的方法和剂量,配制与施用azithromycin二水合物,用以治疗易受细菌感
染者。
本发明由以下实施例加以说明。然而,应该理解到,本发明不限于所述实施例的具体细节。
实施例1
不吸湿的Azithromycin二水合物
方法A
将制备例1的吸湿一水合物(100g;含水量3.1%),四氢呋喃(220ml)和硅藻土(5g)在500ml的锥形烧瓶中混合,搅拌30分钟,然后过滤并用20ml四氢呋喃洗涤。将合并的滤液和洗涤液转移到一个3升的圆底烧瓶中,强烈地搅拌该溶液,加入水(2.0ml)。5分钟后,用5分钟时间加入己烷(1800ml),同时继续剧烈搅拌。经过18小时的粒化后,过滤收集标题产物用1×10ml己烷洗涤,真空干燥至水份为4.6±0.2%(用费歇尔滴定法测定),得到产物89.5g。
方法B
将制备例1的吸湿一水合物(197.6g)和四氢呋喃(430ml)装入反应器中,将该混合物搅拌成乳白色的溶液。加入活性炭(10g)和硅藻土(10g),将混合物搅拌15分钟,然后用800ml己烷稀释,经硅藻土垫板抽吸过滤,并用250ml己烷洗涤。将滤液和洗涤液汇合起来,用己烷将此混合物稀释成2500ml,并加温至34℃。搅拌下,加进24.7ml水。使该混合物冷却至室温,粒化五小时,回收标题产物,如方法A那样干燥,得到177.8g产物。
126℃时,二水合物急剧熔化(加热程度为10℃/分钟);127℃时,差示扫描量热法(加热速率20%/分钟)显示吸热性;热重量分析(加热速率30℃/分钟)表明100℃时,减量1.8%,150℃时减量4.3%;
ir(KBr)3953,3553,3488,2968,2930,2888,2872,2827,2780,2089,1722,1664,1468,1426,1380,1359,1344,1326,1318,1282,1270,1252,1187,1167,1157,1123,1107,1082,1050,1004,993,977,955,930,902,986,879,864,833,803,794,775,756,729,694,671,661,637,598,571,526,
495,459,399,374,321和207cm-1;[alpha]26 D=-41.4°(c=1,CHCl3)。
C38H72N2O12·2H2O的分析计算值:
C,58.14;H,9.77;N,3.57;OCH3,3.95;H2O,4.59.
实测值:
C,58.62;H.9.66;N,3.56;OCH3,4.11;H2O,4.49。
中和当量(0.5N HCl,在1∶1CH3CN∶H2O中):
计算值:374.5,
实测值:393.4。
在33%,75%或100%的相对湿度下,将略经干燥至含水量为4.1%(少于理论值)的二水合物试样迅速吸水,达到二水合物的理论含水量(4.6%)。在33%和75%的相对湿度下,含水量基本上保持恒定,持续时间至少为4天。在100%的相对湿度下,含水量进一步上升至约5.2%,以后三天里,它基本保持稳定含水量。
维持在18%的相对湿度下的相同二水合物试样逐渐失水。在四天时间里,含水量为2.5%;十二天里,含水量为1.1%。
制备例1
吸湿的Azithromycin一水合物
基本上按Kobrehel等的美国专利4,517,359号的甲基化步骤和Bright的美国专利4,474,768号的结晶步骤,搅拌下,将9-去氧-9a-氮杂-9a-高红霉素A(先前称为11-氮杂-10-去氧-10-二氢红霉素A;100g,
0.218mol)溶于400ml CHCl3。在4-5分钟内,加入甲酸(98%;10.4ml,0.436mol)和甲醛(37%;16.4ml,0.349mol),将该混合物加热回流20小时。将该混合物冷却至室温,用400ml水稀释,用50% NaOH将pH调整至10.5。分离水层,用新鲜的CHCl3(2×100ml)萃取。将有机层合并起来,真空汽提至350ml,两次用450ml乙醇稀释,再次汽提至350ml,最后,在一小时内,用1000ml水稀释,在加入约250ml水之后,随着淤浆体开始形成,中止(反应)15分钟。过滤回收标题产物,50℃下风干24小时,得到产物85g,mp136℃;差热分析(加热速率20℃/分)显示142℃时吸热;热重量分析(加热速率30℃/分钟)显示100℃时减量2.6%,150℃时减量4.5%;含水量3.92%;乙醇含量1.09%。
C38H2N2O12的分析计算值(对含乙醇和含水量的校正):
C,58.46;H,9.78;N,3.74;烷氧基,4.67。
实测值:C,58.40;H,9.29;N,3.50;烷氧基,4.52。
将一水合物试样(含水量3.2%)维持在18%的相对湿度下,时间为14天。在开始的24小时内,试样失水,产生理论含水量为2.35%的一水合物。在以后的14天内,含水量基本上保持恒定,即在14天里记录到2.26%的恒定值。
在33%的相对湿度下,同样的一水合物含水量迅速上升至5.6%,至少在三天内基本上维持该值。同样,在75%和100%的相对湿度下,含水量迅速上升,但保持在更高的水平,分别为6.6%和7.2%,至少稳定3天。
Claims (2)
1、一种制备结晶9-去氧-9a-氮杂-9a-甲基-9a-高红霉素A二水合物的方法,该方法包括:将吸湿的9-去氧-9a-氮杂-9a-甲基-9a-高红霉素A一水合物在至少为2摩尔当量水的存在下,从四氢呋喃和(C5-C7)脂族烃的混合物中结晶。
2、按权利要求1的方法,其中的烃是己烷。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US1987/001612 WO1989000576A1 (en) | 1987-07-09 | 1987-07-09 | Azithromycin dihydrate |
USPCT/US87/01612 | 1987-07-09 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1030422A CN1030422A (zh) | 1989-01-18 |
CN1016785B true CN1016785B (zh) | 1992-05-27 |
Family
ID=22202456
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN88104331A Expired CN1016785B (zh) | 1987-07-09 | 1988-07-08 | 9-去氧-9a-氮杂-9a-甲基-高红霉素A二水合物的制备方法 |
Country Status (45)
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1308361C (zh) * | 2004-08-09 | 2007-04-04 | 大连振邦氟涂料股份有限公司 | 乙烯-三氟氯乙烯共聚物的制备方法 |
CN100366686C (zh) * | 2006-01-12 | 2008-02-06 | 济南瑞氟化工科技有限公司 | 一种氟硅超双疏不粘涂料 |
Families Citing this family (74)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HRP20020231A2 (en) * | 2002-03-18 | 2003-12-31 | Pliva D D | ISOSTRUCTURAL PSEUDOPOLYMORPHS OF 9-DEOXO-9a-AZA-9a-METHYL-9a-HOMOERYTHROMYCIN A |
US5912331A (en) * | 1991-03-15 | 1999-06-15 | Merck & Co., Inc. | Process for the preparation of 9-deoxo-9(Z)-hydroxyiminoerythromycin A |
US5985844A (en) * | 1992-03-26 | 1999-11-16 | Merck & Co., Inc. | Homoerythromycin A derivatives modified at the 4"-and 8A-positions |
US5189159A (en) * | 1992-04-02 | 1993-02-23 | Merck & Co., Inc. | 8a-AZA-8a-homoerythromycin cyclic iminoethers |
EP0539223A1 (en) * | 1991-10-25 | 1993-04-28 | Ono Pharmaceutical Co., Ltd. | Glycine derivative monosodium salt tetrahydrate having an inhibitory effect on elastase |
US5215980A (en) * | 1992-01-17 | 1993-06-01 | Merck & Co., Inc. | 10-AZA-9-deoxo-11-deoxy-erythromycin A and derivatives thereof |
US5210235A (en) * | 1992-08-26 | 1993-05-11 | Merck & Co., Inc. | Methods of elaborating erythromycin fragments into amine-containing fragments of azalide antibiotics |
US5332807A (en) * | 1993-04-14 | 1994-07-26 | Merck & Co., Inc. | Process of producing 8A- and 9A-azalide antibiotics |
CN1034734C (zh) * | 1993-12-10 | 1997-04-30 | 北京市集才药物研究所 | 一种新的阿齐红霉素结晶及其制备方法 |
US5605889A (en) | 1994-04-29 | 1997-02-25 | Pfizer Inc. | Method of administering azithromycin |
JP2977907B2 (ja) | 1994-05-06 | 1999-11-15 | ファイザー・インコーポレーテッド | アジスロマイシンの放出調節された剤形 |
ES2122905B1 (es) * | 1996-07-11 | 1999-11-16 | Astur Pharma Sa | Sintesis de 11,12-hidrogenoortoborato de 9-desoxo-9a-aza-11,12-desoxi-9a-metil-9a-homoeritromicina a. un procedimiento para la preparacion de 9-desoxo-9a-aza-9a-metil-9a-homoeritromicina a dihidrato (azitromicina dihidrato). |
US6369035B1 (en) * | 1997-10-16 | 2002-04-09 | Pliva, Farmaceutska Industrja, Dioni{Haeck Over (C)}Ko Dru{Haeck Over (S)}Tvo | 3,6-hemiketals from the class of 9A-azalides |
US6861411B1 (en) | 1997-12-02 | 2005-03-01 | Pfizer, Inc. | Method of treating eye infections with azithromycin |
PT102130A (pt) * | 1998-03-13 | 1999-09-30 | Hovione Sociedade Quimica S A | Processo de preparacao de dihidrato de azitromicina |
TW546302B (en) * | 1998-05-08 | 2003-08-11 | Biochemie Sa | Improvements in macrolide production |
CA2245398C (en) | 1998-08-21 | 2002-01-29 | Apotex Inc. | Azithromycin monohydrate isopropanol clathrate and methods for the manufacture thereof |
PT1152765E (pt) * | 1998-11-30 | 2004-12-31 | Teva Pharma | Etanolato de azitromicina, processo de preparacao e composicoes farmaceuticas que os contem |
US7056893B2 (en) | 1999-03-31 | 2006-06-06 | Insite Vision, Inc. | Topical treatment for prevention of ocular infections |
US6239113B1 (en) | 1999-03-31 | 2001-05-29 | Insite Vision, Incorporated | Topical treatment or prevention of ocular infections |
OA11876A (en) * | 1999-05-18 | 2006-03-27 | Pfizer Prod Inc | Novel crystalline forms of a macrolide antibiotic. |
KR100700475B1 (ko) | 1999-06-29 | 2007-03-28 | 바이오케미 에스.에이. | 마크롤라이드 |
ES2177373B1 (es) * | 1999-11-26 | 2003-11-01 | Astur Pharma Sa | Preparacion de azitromicina en su forma no cristalina |
DE60133083D1 (de) | 2000-01-04 | 2008-04-17 | Teva Pharma | Verfahren zur herstellung von azithromycin-dihydrat |
ES2162764B1 (es) * | 2000-05-17 | 2003-04-01 | Ercros Ind Sa | Forma polimorfica del dihidrato de azitromicina, y su procedimiento deobtencion. |
DE60026718T2 (de) | 2000-07-25 | 2006-11-16 | Laboratorio Silanes, S.A. De C.V. | Einstufiges verfahren zur herstellung von 7,16-deoxy-2-aza-10-o-cladinosil-12-o-desosaminil-4,5-dihydroxi-6-ethyl-3,5,9,11,13,15-hexamethylbicycle(11.2.11)hexadeca-1(2)-en-8-ona undeine neue form von 9-desoxo-9a-methyl-9a-aza-9a-homoerythromycin a |
ES2172417B1 (es) * | 2000-07-31 | 2003-09-16 | Sint Quimica Sa | Nueva forma mejorada de azitromicina monohidrato de menor higroscopicidad, procedimiento de preparacion y composiciones farmaceuticas que la comprenden. |
ATE306491T1 (de) | 2000-08-23 | 2005-10-15 | Wockhardt Ltd | Verfahren zur herstellung von wasserfreiem azithromycin |
CZ303343B6 (cs) * | 2000-11-27 | 2012-08-08 | Sandoz Ag | Zpusob prípravy azithromycinu ve forme monohydrátu |
IN190080B (zh) * | 2001-01-29 | 2003-06-07 | Alembic Ltd | |
KR100491183B1 (ko) * | 2001-03-21 | 2005-05-25 | 한미약품 주식회사 | 아지트로마이신의 제조방법 및 이 방법에 사용되는9-데옥소-9에이-아자-9에이-호모에리트로마이신 에이의결정성 수화물 |
EP1671979B1 (en) | 2001-05-22 | 2008-08-13 | Pfizer Products Inc. | New Cristal Form of Azithromycin |
EA007618B1 (ru) | 2001-05-22 | 2006-12-29 | Пфайзер Продактс Инк. | Кристаллический полуторогидрат азитромицина, содержащая его фармацевтическая композиция и способ лечения на его основе |
US6861413B2 (en) | 2001-05-22 | 2005-03-01 | Pfizer Inc. | Stable non-dihydrate azithromycin oral suspensions |
SK1012004A3 (sk) * | 2001-08-21 | 2005-04-01 | Pfizer Products Inc. | Použitie azitromycínu na výrobu liečiva na liečenie respiračných infekcií u človeka |
BR0215175A (pt) * | 2001-12-21 | 2004-12-28 | Pfizer Prod Inc | Métodos para a granulação úmida de azitromicina |
NZ532707A (en) * | 2001-12-21 | 2006-07-28 | Pfizer Prod Inc | Directly compressible formulations of azithromycin |
JP2005526020A (ja) * | 2002-02-01 | 2005-09-02 | ファイザー・プロダクツ・インク | アジスロマイシンの乾式造粒配合物 |
US7376064B2 (en) | 2002-02-25 | 2008-05-20 | Samsung Electronics Co., Ltd. | Method and apparatus for recording data on optical recording medium |
ITMI20021209A1 (it) * | 2002-06-04 | 2003-12-04 | Chemi Spa | Processo di preparazione di azitromicina ad elevata purezza |
US6855813B2 (en) * | 2002-07-19 | 2005-02-15 | Alembic Limited | Process for the preparation of azithromycin monohydrate |
HRP20020614A2 (en) | 2002-07-22 | 2004-06-30 | PLIVA-ISTRAŽIVAČKI INSTITUT d.o.o. | Rhombic pseudopolymorph of 9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin a |
GB2395482A (en) * | 2003-07-03 | 2004-05-26 | Jubilant Organosys Ltd | Process for preparing non-hygroscopic azithromycin dihydrate |
US20050013835A1 (en) * | 2003-07-15 | 2005-01-20 | Pfizer Inc. | Stable non-dihydrate azithromycin oral suspensions |
CA2549225A1 (en) * | 2003-12-04 | 2005-06-16 | Pfizer Products Inc. | Spray-congeal process using an extruder for preparing multiparticulate crystalline drug compositions containing preferably a poloxamer and a glyceride |
RU2006119453A (ru) * | 2003-12-04 | 2007-12-20 | Пфайзер Продактс Инк. (Us) | Получение посредством основанных на применении жидкостей способов лекарственные формы азитромицина с большим количеством частиц |
US6984403B2 (en) * | 2003-12-04 | 2006-01-10 | Pfizer Inc. | Azithromycin dosage forms with reduced side effects |
WO2005053639A2 (en) * | 2003-12-04 | 2005-06-16 | Pfizer Products Inc. | Controlled release multiparticulates formed with dissolution enhancers |
EP1691787B1 (en) * | 2003-12-04 | 2008-07-02 | Pfizer Products Inc. | Method for making pharmaceutical multiparticulates |
WO2005053653A1 (en) * | 2003-12-04 | 2005-06-16 | Pfizer Products Inc. | Spray-congeal process using an extruder for preparing multiparticulate azithromycin compositions containing preferably a poloxamer and a glyceride |
WO2005053652A1 (en) | 2003-12-04 | 2005-06-16 | Pfizer Products Inc. | Multiparticulate crystalline drug compositions containing a poloxamer and a glyceride |
BRPI0416534A (pt) * | 2003-12-04 | 2007-01-09 | Pfizer Prod Inc | composições multiparticuladas com estabilidade melhorada |
US7468428B2 (en) * | 2004-03-17 | 2008-12-23 | App Pharmaceuticals, Llc | Lyophilized azithromycin formulation |
US20060116336A1 (en) * | 2004-03-17 | 2006-06-01 | American Pharmaceutical Partners, Inc. | Lyophilized azithromycin formulation |
US7235646B2 (en) | 2004-06-28 | 2007-06-26 | Alembic Limited | Process for the preparation of azithromycin monohydrate isopropanol clathrate |
US7683162B2 (en) * | 2004-08-30 | 2010-03-23 | Taro Pharmaceutical Industries Limited | Process of preparing a crystalline azithromycin monohydrate |
TWI315310B (en) * | 2004-12-01 | 2009-10-01 | Teva Gyogyszergyar Zartkoruen Mukodo Reszvenytarsasag | Methods of preparing pimecrolimus |
US20080199527A1 (en) * | 2004-12-21 | 2008-08-21 | Pfizer Inc. | Enteric Coated Azithromycin Multiparticulates |
US8546423B2 (en) | 2005-05-18 | 2013-10-01 | Mpex Pharmaceuticals, Inc. | Aerosolized fluoroquinolones and uses thereof |
JP2009539866A (ja) * | 2006-06-05 | 2009-11-19 | オースペックス・ファーマシューティカルズ・インコーポレイテッド | 置換エリスロマイシンアナログの調製および有用性 |
US7704959B2 (en) | 2006-10-03 | 2010-04-27 | Dow Pharmaceutical Sciences | Azithromycin for the treatment of nodular acne |
US20090062220A1 (en) * | 2007-08-29 | 2009-03-05 | Protia, Llc | Deuterium-enriched azithromycin |
CN101177441B (zh) * | 2007-12-05 | 2012-05-23 | 浙江耐司康药业有限公司 | 一种稳定的阿奇霉素一水合物结晶的制备方法 |
CN101624412B (zh) * | 2008-07-10 | 2012-07-04 | 刘力 | 大环内酯类衍生物及其制备和用途 |
NZ592717A (en) | 2008-10-07 | 2013-03-28 | Mpex Pharmaceuticals Inc | Aerosol fluoroquinolone formulations for improved pharmacokinetics comprising levofloxacin or ofloxacin and a di- or trivalent cation |
SI2346509T1 (sl) | 2008-10-07 | 2020-08-31 | Horizon Orphan Llc | Inhalacija levofloksacina za zmanjšanje vnetja pljuč |
CN101418026B (zh) * | 2008-10-09 | 2011-05-18 | 南京工业大学 | 一种晶型和粒度可控的阿奇霉素结晶工艺 |
CN101787063B (zh) * | 2009-01-23 | 2012-12-19 | 刘力 | 抗感染药物及其制备和用途 |
BRPI1009823A2 (pt) | 2009-03-13 | 2019-09-24 | Da Volterra Assistance Publique Hopitaux De Paris E Univ Paris Diderot Paris 7 | "composição compreendendo um sistema de dispensação de droga, conjunto de uma primeira e uma segunda composição, e, kit." |
RU2563809C2 (ru) | 2009-09-04 | 2015-09-20 | Мпекс Фармасьютикалс, Инк. | Применение левофлоксацина в форме аэрозоля для лечения муковисцидоза |
CN102911219A (zh) * | 2011-08-03 | 2013-02-06 | 山东方明药业集团股份有限公司 | 一种阿齐霉素在水相直接结晶的方法 |
CN103159811A (zh) * | 2011-12-10 | 2013-06-19 | 山东方明药业集团股份有限公司 | 一种阿齐霉素中间体9a-脱氧-9a-氮杂-9a-高红霉素A的制备方法 |
WO2013088274A1 (en) | 2011-12-14 | 2013-06-20 | Wockhardt Limited | Anhydrous amorphous azithromycin composition free of azithromycin dihydrate |
CN102417531B (zh) * | 2011-12-20 | 2014-06-11 | 浙江国邦药业有限公司 | 一种阿奇霉素一水合物的制备方法 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4020270A (en) * | 1974-05-02 | 1977-04-26 | Societa' Farmaceutici Italia S.P.A. | L-lyxohex-1-enopyranose derivative |
US4219641A (en) * | 1979-06-14 | 1980-08-26 | The Upjohn Company | Process for preparing erythromycin succinate |
SI8110592A8 (en) | 1981-03-06 | 1996-06-30 | Pliva Pharm & Chem Works | Process for preparing of n-methyl-11-aza-10-deoxo-10-dihydroerythromycine a and derivatives thereof |
US4474768A (en) * | 1982-07-19 | 1984-10-02 | Pfizer Inc. | N-Methyl 11-aza-10-deoxo-10-dihydro-erytromycin A, intermediates therefor |
US4526889A (en) * | 1982-11-15 | 1985-07-02 | Pfizer Inc. | Epimeric azahomoerythromycin A derivative, intermediates and method of use |
PH19293A (en) * | 1982-11-15 | 1986-03-04 | Pfizer | Epimeric azahomoerythromycin,pharmaceutical composition containing the same and method of use thereof |
US4512982A (en) * | 1984-04-13 | 1985-04-23 | Pfizer Inc. | 9α-Aza-9α-homoerythromycin compounds, pharmaceutical composition and therapeutic method |
YU43402B (en) * | 1985-03-04 | 1989-06-30 | Pliva Pharm & Chem Works | Process for preparation of 11-aza-10-deoxo-10-dihydroeritromycin "a" by using electro-chemical reduction |
WO1989002271A1 (en) | 1987-09-10 | 1989-03-23 | Pfizer | Azithromycin and derivatives as antiprotozoal agents |
-
1987
- 1987-07-09 UA UA93004522A patent/UA27040C2/uk unknown
- 1987-07-09 WO PCT/US1987/001612 patent/WO1989000576A1/en active IP Right Grant
- 1987-07-09 RO RO143593A patent/RO107257B1/ro unknown
- 1987-07-09 MX MX1221388A patent/MX12213A/es unknown
- 1987-07-09 RU SU874742955A patent/RU2066324C1/ru active
-
1988
- 1988-05-11 IN IN418/DEL/88A patent/IN168879B/en unknown
- 1988-06-15 AP APAP/P/1988/000093A patent/AP44A/en active
- 1988-06-28 EP EP88305921A patent/EP0298650B1/en not_active Expired - Lifetime
- 1988-06-28 ES ES198888305921T patent/ES2038756T3/es not_active Expired - Lifetime
- 1988-06-28 AT AT88305921T patent/ATE72446T1/de not_active IP Right Cessation
- 1988-06-28 DE DE8888305921T patent/DE3868296D1/de not_active Expired - Lifetime
- 1988-07-04 IL IL86979A patent/IL86979A/xx not_active IP Right Cessation
- 1988-07-05 MY MYPI88000744A patent/MY103744A/en unknown
- 1988-07-05 BG BG84783A patent/BG47348A3/xx unknown
- 1988-07-06 JP JP63168637A patent/JPH0631300B2/ja not_active Expired - Lifetime
- 1988-07-06 CS CS884896A patent/CS272241B2/cs not_active IP Right Cessation
- 1988-07-07 CA CA000571381A patent/CA1314876C/en not_active Expired - Lifetime
- 1988-07-07 IS IS3370A patent/IS1540B/is unknown
- 1988-07-07 PL PL1988273590A patent/PL157145B1/pl unknown
- 1988-07-07 PT PT87933A patent/PT87933B/pt not_active IP Right Cessation
- 1988-07-07 AR AR88311356A patent/AR243532A1/es active
- 1988-07-07 PH PH37189A patent/PH30953A/en unknown
- 1988-07-07 DD DD88317672A patent/DD271705A5/de unknown
- 1988-07-07 EG EG376/88A patent/EG18527A/xx active
- 1988-07-08 AU AU18839/88A patent/AU604553B2/en not_active Expired
- 1988-07-08 KR KR1019880008463A patent/KR900006218B1/ko not_active IP Right Cessation
- 1988-07-08 IE IE210888A patent/IE60354B1/en not_active IP Right Cessation
- 1988-07-08 SI SI8811325A patent/SI8811325A8/sl unknown
- 1988-07-08 OA OA59384A patent/OA08743A/xx unknown
- 1988-07-08 ZA ZA884925A patent/ZA884925B/xx unknown
- 1988-07-08 YU YU1325/88A patent/YU45075B/xx unknown
- 1988-07-08 CN CN88104331A patent/CN1016785B/zh not_active Expired
- 1988-07-08 DK DK198803806A patent/DK172573B1/da not_active IP Right Cessation
- 1988-07-08 NZ NZ225338A patent/NZ225338A/xx unknown
- 1988-07-11 MA MA21565A patent/MA21323A1/fr unknown
-
1990
- 1990-01-08 FI FI900087A patent/FI91263C/fi not_active IP Right Cessation
- 1990-01-08 NO NO90900077A patent/NO171556C/no not_active IP Right Cessation
-
1992
- 1992-02-06 GR GR920400067T patent/GR3003737T3/el unknown
- 1992-12-21 US US07/994,040 patent/US6268489B1/en not_active Expired - Lifetime
-
1993
- 1993-11-17 LV LVP-93-1240A patent/LV10624B/xx unknown
-
1994
- 1994-02-22 SG SG27794A patent/SG27794G/en unknown
- 1994-11-17 HK HK127594A patent/HK127594A/xx not_active IP Right Cessation
-
1995
- 1995-06-30 HU HU95P/P00738P patent/HU211862A9/hu unknown
- 1995-10-20 CY CY177695A patent/CY1776A/xx unknown
-
1998
- 1998-03-30 BA BA980213A patent/BA98213B1/bs active
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1308361C (zh) * | 2004-08-09 | 2007-04-04 | 大连振邦氟涂料股份有限公司 | 乙烯-三氟氯乙烯共聚物的制备方法 |
CN100366686C (zh) * | 2006-01-12 | 2008-02-06 | 济南瑞氟化工科技有限公司 | 一种氟硅超双疏不粘涂料 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1016785B (zh) | 9-去氧-9a-氮杂-9a-甲基-高红霉素A二水合物的制备方法 | |
CN1144790C (zh) | 泰米沙丹的多晶型物,其制备方法及其在制备药物组合物中的用途 | |
CN101778858B (zh) | 大环内酯固态晶型 | |
CA2584365A1 (en) | Ascomycin crystalline forms and preparation thereof | |
US7186842B2 (en) | Polymorph of (1-benzyl-4-[(5,6-dimethoxy-1-indanone)-2-y1] methyl piperidine hydrochloride (Donepezil hydrochloride) and a process for producing thereof | |
CN1028428C (zh) | 23-(c1-c6烷基肟)-ll-f28249化合物的制备方法 | |
AU2004320911A8 (en) | 1-benzyl-4-[(5,6-dimethoxy-1-indanone)-2-yl] methyl piperidine oxalate (donepezil oxalate) and its polymorphs | |
CN1041933C (zh) | 克拉维酸的二胺盐及其制备方法和用途 | |
EP0506979B1 (en) | Organic polymer compound and production thereof | |
CN103562183B (zh) | 奥米沙班的苯甲酸盐 | |
US20070123565A1 (en) | Donepezil Hydrochloride Form VI | |
CN102382169B (zh) | 阿加曲班单一立体异构体的分离方法及多晶型物 | |
CN108570045B (zh) | 氢溴酸山莨菪碱的晶型、其制备方法、药物组合物 | |
KR20020050282A (ko) | 베타-디-5-티옥실로스 유도체, 제조방법 및 약학적 용도 | |
CN112694488B (zh) | 一种l型头孢孟多酯钠的合成方法 | |
JPH093088A (ja) | アミノ二糖及びキチン又はその類似多糖類の製造方法 | |
EP0619816A1 (en) | A process for the resolution of (+-)-alpha-[2-[acetyl(1-methylethyl)amino]ethyl]-alpha-(2-chlorophenyl)-1-piperidinebutanamide | |
CN114149360B (zh) | 一种高纯度尼群地平原料药的制备方法 | |
EP0548834B1 (en) | Stable hexahydrate of etoposide 4'-phosphate disodium salt | |
CA1274842A (en) | Esters of o(2,6-dichlorphenylamino)phenylacetic acid and method for their preparing | |
CN114773415A (zh) | 一种无保基双臂化含糖化合物及其制备方法 | |
CN102329371A (zh) | 阿加曲班单一立体异构体的分离方法及多晶型物 | |
CN1854142A (zh) | 呋脲苄青霉素钠的结晶方法 | |
WO1999033797A1 (en) | NEW CRYSTALLINE POLYMORPHIC FORM OF 1-METHYL-5-p-TOLUOYLPYRROLE-2-ACETAMIDOACETIC ACID GUAIACYL ESTER (MED 15) | |
CN1269354A (zh) | 再结晶1,3-二(氨基苯氧基苯)的方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C06 | Publication | ||
PB01 | Publication | ||
C13 | Decision | ||
GR02 | Examined patent application | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C15 | Extension of patent right duration from 15 to 20 years for appl. with date before 31.12.1992 and still valid on 11.12.2001 (patent law change 1993) | ||
OR01 | Other related matters | ||
C17 | Cessation of patent right | ||
CX01 | Expiry of patent term |